Open AccessSevere gastritis due to pembrolizumab treatment in a lung cancer patient
Author(s) -
Hayama Noriko,
Ihara Hiroaki,
Honma Yuichirou,
Itoigawa Yukinari,
Kaira Kyoichi,
Fujii Mitsuhiro
Publication year - 2020
Publication title -
respirology case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.304
H-Index - 9
ISSN - 2051-3380
DOI - 10.1002/rcr2.636
Subject(s) - medicine , pembrolizumab , colitis , inflammatory bowel disease , gastritis , lung cancer , cancer , gastroenterology , disease , colorectal cancer , autoimmune gastritis , immunology , immunotherapy , stomach
Immune checkpoint inhibitors (ICIs) are known to induce gastrointestinal adverse events. Colitis occurs most frequently, and gastritis is less common. A few case reports of gastritis induced by ICIs have indicated that colitis induced by cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4) resembles inflammatory bowel disease (IBD) and that programmed death‐1/programmed death ligand‐1 (PD‐1/PD‐L1) inhibitor can also induce the same type of colitis. We herein encountered a case of gastritis arising after 25 cycles of pembrolizumab administration in which the pathological and endoscopic findings resembled those of IBD. ICIs may induce gastritis in a manner similar to the pathogenesis of IBD.